Definium Therapeutics
Coverage of Definium Therapeutics in the Nexus archive.
- LSD's Depression Win; Summer Heat and Suicide; Antipsychotic Nonresponse Predictors
A phase III trial of an investigational LSD-based pill (DT120) showed it met primary and key secondary endpoints in treating adults with major depressive disorder, according to Definium Therapeutics. The results suggest potential efficacy for the treatment of depression.
- Definium’s shares surge 55% after LSD-based depression pill delivers strong results
Definium Therapeutics reported that a single dose of its LSD-based experimental pill significantly reduced major depression symptoms in a late-stage trial, leading to a 55% surge in its shares to a four-year high. Patients on the drug recorded lower depression scale scores than those on placebo after six weeks.
- STAT+: Definium LSD therapy helped patients with major depression in late-stage trial
Definium Therapeutics' LSD therapy (DT120) showed significant improvement in patients with major depression during a Phase 3 trial. Patients experienced a 13.3-point drop on the MADRS depression test at six weeks compared to 5.2 points in the placebo group, with effects maintained at 12 weeks.
- Bergman: ‘The time is now’ to push for breakthroughs in psychedelic treatments
Representative Jack Bergman pushes for breakthroughs in psychedelic treatments, citing President Trump's recent support. Bergman co-founded Congressional Psychedelics Advancing Therapies. The effort aims to address America's mental health crisis.